A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
This will be a multicenter, open-label study enrolling a total of up to 23 patients.
Metastatic Colorectal Cancer
DRUG: bevacizumab|DRUG: FOLFOX|DRUG: PRO95780
Incidence and nature of dose-limiting toxicities, Length and study
Incidence, nature, and severity of adverse events, Length of study|Change in vital signs, Length of study|Incidence and severity of infusion reactions, Length of study|Change in clinical laboratory results, Length of study|Incidence of anti-PRO95780 antibodies, Length of study
This will be a multicenter, open-label study enrolling a total of up to 23 patients.